PTPRC and neoplasm: To evaluate the possibility to improve tumor-specific immune responses by immune checkpoint-blockade, we determined expression of the two PD-1 ligands, PD-L1 and PD-L2 on immune cells and tumor epithelial cells (defined as CD45-EpCAM+ cells).